- Entire Pipeline
- Discovery & Early Development
- Pre-clinical & Clinical Development
- Limited Market Availability
Displaying 241 - 243 of 243
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: β-human chorionic gonadotropin
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Talwar Research Foundation, Indian Council for Medical Research
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Pages
Displaying 21 - 30 of 70
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Prototype Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Alternative Name: K4K20S4
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other, Other
Development Stage: Lead Optimization
Alternative Name: Plasma Membrane Calcium ATPase (PMCA) Inhibitors
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: University of Manchester, Max Planck Institute
Alternative Name: Electrospun fiber meshes
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Development Stage: Prototype Development
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Contraline, LLC
Development Stage: Lead Optimization
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development
Pages
Displaying 31 - 40 of 121
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Alternative Name: Single Rod GES Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Phase III
Alternative Name: GES VR
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Pre-clinical
Pages
Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved
Pages
